

Bulley, Margaret

From: labclientservice
Sent: Tuesday, September 11, 2018 3:59 PM
To: GME PC; Ortolf, Barbara; Salvatore, Alicia; Regional Physicians Group Directors of Operations; Regional Physician Group Practice Managers; Regional Physician Group Physicians; CPUP Managers; CPUP DOO's; CPUP Business Administrators
Cc: Fogt, Franz; Atweh, Mahmoud (Michael); Hunt, William; Nachamkin, Irving; Mincarelli, Deborah; Bulley, Margaret; Danoski, Daniel; McLaughlin, Cara; _Leonard, Sarah; Long, Jeff; Baylock, Audrey; Metheny, Robert; Eller, Kara; Bryant Knox, Shanon; Wang, Ping (HUP Path and Lab); _Rulander, Nichole; Klenk, Russell; Gordon, Stephanie; Kirn, Donna; Halliday, Joyce; Korczak, Kristy (Morris); Acker, David; Agront, Sarita; Bahar, Wael Y; Kim, Sharon; Macchione, Gerald; Mcaleer, Diane S
Subject: PENN MEDICINE - Ultra-sensitive PSA
Attachments: UltraPSA_Sept2018.docx



Penn Medicine

University of Pennsylvania Health System

TO: UPHS Physicians and Staff

FROM: Department of Pathology and Laboratory Medicine
Ping Wang, Ph.D., DABCC, FACB, Director of Clinical Chemistry and Core Laboratory

SUBJECT: Ultra-sensitive PSA

Effective September 11, ultra-sensitive PSA testing will transition from send-out laboratory ARUP to in-house testing in the Core Laboratory at the Hospital of the University of Pennsylvania.

Ultra-sensitive PSA is used to detect prostate cancer recurrence after radical prostatectomy, and is reported with a lower limit of quantitation of 0.01 ng/mL. This test should not be used for prostate cancer screening, or monitoring of prostate cancer patients before radical prostatectomy. Cutoff of ultra-sensitive PSA to indicate biochemical recurrence has not been well established, and ranges from 0.01 to 0.05 ng/mL in different studies. Interpretation of a detectable ultra-sensitive PSA result should be made in conjunction with other clinicopathologic factors. The test is available in Pennchart as orderable PSA ULTRA SENSITIVE (C9044300).

Please direct any questions related to clinical correlation and interpretation to Dr. Ping Wang (Ping.Wang2@uphs.upenn.edu), or test ordering and reporting to Nichole Rulander (Nichole.Rulander@uphs.upenn.edu). Thank you.

Ping Wang, PhD, DABCC, FACB
Director of Clinical Chemistry and Core Laboratory